Jay P. Powers

2.8k citations

66 papers · 1.7k indexed · h-index 21

Impact in

Physiology top 2%
- Adenosine and Purinergic Signaling
Immunology top 5%
- Complement system in diseases
- Immune Response and Inflammation
- Immunotherapy and Immune Responses

Papers in ⓘ

Physiology 18
- Adenosine and Purinergic Signaling 18
Oncology 27
- Chemokine receptors and signaling 11
- Peptidase Inhibition and Analysis 5

Co-authors: Juan C. Jaén (27 shared papers)Thomas J. Schall (12 shared papers)Nigel P.C. Walker (11 shared papers)Zhulun Wang (10 shared papers)Scott D. Rychnovsky (5 shared papers)Lisa Seitz (11 shared papers)Daniel J. Dairaghi (7 shared papers)Mark E.T. Penfold (2 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (9 papers)Cancer Research (9 papers)Cancer Immunology Research (5 papers)Organic Process Research & Development (4 papers)Journal of Medicinal Chemistry (4 papers)
Partner nations: United States Switzerland Canada

In The Last Decade

Jay P. Powers

62 papers receiving 1.7k citations

Peers

Countries citing papers authored by Jay P. Powers

Since Specialization

Citations

This map shows the geographic impact of Jay P. Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay P. Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay P. Powers more than expected).

Fields of papers citing papers by Jay P. Powers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay P. Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay P. Powers. The network helps show where Jay P. Powers may publish in the future.

Co-authors

The 25 scholars most cited alongside Jay P. Powers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jay P. Powers Line = papers co-authored together Jay P. Powers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN Journal of the American Society of Nephrology ·Hong Xiao, Daniel J. Dairaghi, Jay P. Powers, Linda Ertl, Trageen Baumgart, Yu Wang, Lisa Seitz, Mark E.T. Penfold, Lin Gan, Peiqi Hu, Bao Lu, Norma P. Gerard, Craig Gérard, Thomas J. Schall, Juan C. Jaén, Ronald J. Falk, J. Charles Jennette	2013	257
2	Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands The Journal of Immunology ·Brian A. Zabel, Yu Wang, Susanna Lewén, Robert Berahovich, Mark E.T. Penfold, Penglie Zhang, Jay P. Powers, Bretton C. Summers, Zhenhua Miao, Bin Zhao, Ali Jalili, Anna Janowska‐Wieczorek, Juan C. Jaén, Thomas J. Schall	2009	245
3	Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper Structure ·Zhulun Wang, Jinsong Liu, Athena Sudom, Merrill Ayres, Shyun Li, Holger Wesche, Jay P. Powers, Nigel P.C. Walker	2006	116
4	Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study PLoS ONE ·Pirow Bekker, Daniel J. Dairaghi, Lisa Seitz, Manmohan R. Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel E. Johnson, Jay P. Powers, Juan C. Jaén, Israel Charo, Thomas J. Schall	2016	115
5	SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase Journal of Medicinal Chemistry ·Jay P. Powers, Derek E. Piper, Yang Li, V. Mayorga, John V. Anzola, James Chen, Juan C. Jaén, Gary Lee, Jinqian Liu, M.G. Peterson, George Tonn, Qiuping Ye, Nigel P.C. Walker, Zhulun Wang	2006	112
6	Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4 Bioorganic & Medicinal Chemistry Letters ·Jay P. Powers, Shyun Li, Juan C. Jaén, Jinqian Liu, Nigel P.C. Walker, Zhulun Wang, Holger Wesche	2006	99
7	CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice American Journal of Physiology-Renal Physiology ·Timothy J. Sullivan, Zhenhua Miao, Daniel J. Dairaghi, Antoni Krasinski, Yu Wang, Bin Zhao, Trageen Baumgart, Linda Ertl, Andrew M. K. Pennell, Lisa Seitz, Jay P. Powers, Ruiping Zhao, S Ungashe, Zheng Wei, Landin Boring, Chia-Lin Tsou, Israel Charo, Robert Berahovich, Thomas J. Schall, Juan C. Jaén	2013	76
8	CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease Blood ·Daniel J. Dairaghi, Babatunde O. Oyajobi, Anjana Gupta, Brandon McCluskey, Shichang Miao, Jay P. Powers, Lisa Seitz, Yu Wang, Yibin Zeng, Penglie Zhang, Thomas J. Schall, Juan C. Jaén	2012	62
9	Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39 Journal of Medicinal Chemistry ·Jenna L. Jeffrey, Kenneth V. Lawson, Jay P. Powers	2020	59
10	Conformation and reactivity of anomeric radicals Journal of the American Chemical Society ·Scott D. Rychnovsky, Jay P. Powers, Teresa J. LePage	1992	50
11	Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers Investigational New Drugs ·Lisa Seitz, Lixia Jin, Manmohan R. Leleti, Devika Ashok, Jenna L. Jeffrey, Aimee Rieger, Renger G. Tiessen, Gerhard Arold, Joanne B.L. Tan, Jay P. Powers, Matthew J. Walters, Joyson Karakunnel	2018	48
12	Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes Metabolism ·Timothy J. Sullivan, Zhenhua Miao, Bin Zhao, Linda Ertl, Yu Wang, Antoni Krasinski, Matthew J. Walters, Jay P. Powers, Daniel J. Dairaghi, Trageen Baumgart, Lisa Seitz, Robert Berahovich, Thomas J. Schall, Juan C. Jaén	2013	43
13	Chair and twist-boat conformations of 1,3-dioxanes: limitations of molecular mechanics force fields The Journal of Organic Chemistry ·Scott D. Rychnovsky, Yang Guang, Jay P. Powers	1993	42
14	Novel Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerases Journal of Molecular Biology ·Gary Lee, Derek E. Piper, Zhulun Wang, John V. Anzola, Jay P. Powers, Nigel P.C. Walker, Yang Li	2006	34
15	Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 Bioorganic & Medicinal Chemistry ·Hua Tu, Jay P. Powers, Jinsong Liu, Stefania Ursu, Athena Sudom, Xuelei Yan, Haoda Xu, David Meininger, Michael DeGraffenreid, Xiaodong He, Juan C. Jaén, Daqing Sun, Marc Labelle, Hiroshi Yamamoto, Bei Shan, Nigel P.C. Walker, Zhulun Wang	2008	30
16	Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Bioorganic & Medicinal Chemistry Letters ·Daqing Sun, Zhulun Wang, Yongmei Di, Juan C. Jaén, Marc Labelle, Ji Ma, Shichang Miao, Athena Sudom, Liang Tang, Craig S. Tomooka, Hua Tu, Stefania Ursu, Nigel P.C. Walker, Xuelei Yan, Qiuping Ye, Jay P. Powers	2008	28
17	Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors Journal of Medicinal Chemistry ·Ehesan U. Sharif, Jarosław Kalisiak, Kenneth V. Lawson, Dillon H. Miles, Eric T. Newcomb, Erick A. Lindsey, Brandon R. Rosen, Laurent Debien, Ada Chen, Xiaoning Zhao, Stephen W. Young, Nigel P.C. Walker, Norbert Sträter, Emma Rose Scaletti, Lixia Jin, Guifen Xu, Manmohan R. Leleti, Jay P. Powers	2021	26
18	Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Yosup Rew, Dustin L. McMinn, Zhulun Wang, Xiaodong He, Randall W. Hungate, Juan C. Jaén, Athena Sudom, Daqing Sun, Hua Tu, Stefania Ursu, Elisia Villemure, Nigel P.C. Walker, Xuelei Yan, Qiuping Ye, Jay P. Powers	2009	23
19	Nonequilibrium Radical Reductions Journal of the American Chemical Society ·Alexandre J. Buckmelter, Jay P. Powers, Scott D. Rychnovsky	1998	23
20	Cascade Cyclizations of Cyclic Sulfates: An Enantioselective Alternative to Polyepoxide Cyclizations in the Synthesis of Poly(tetrahydrofurans) Journal of the American Chemical Society ·Thomas J. Beauchamp, Jay P. Powers, Scott D. Rychnovsky	1995	22

About Jay P. Powers

Jay P. Powers is a scholar working on Physiology, Oncology, Immunology, Organic Chemistry and Biotechnology, having authored 66 papers that have together received 1.7k indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (11 papers), Chemokine receptors and signaling (11 papers), Hormonal Regulation and Hypertension (7 papers), Click Chemistry and Applications (6 papers), Peptidase Inhibition and Analysis (5 papers), Adrenal and Paraganglionic Tumors (5 papers) and Cancer Research and Treatments (4 papers). The work is most often cited by research in Physiology (157 citations), Immunology (667 citations), Nephrology (160 citations), Oncology (400 citations) and Genetics (131 citations). Jay P. Powers has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Juan C. Jaén, Thomas J. Schall, Nigel P.C. Walker, Zhulun Wang, Scott D. Rychnovsky, Lisa Seitz, Daniel J. Dairaghi, Mark E.T. Penfold, Linda Ertl and Penglie Zhang. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Research, Cancer Immunology Research, Organic Process Research & Development and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact